Home Self Admin denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for home self admin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Limits the Quantity of Home Self-Administration Supplies — and How to Appeal

A quantity-limit denial for home self-administration typically means Humana's system has capped the number of units, administration kits, or supply refills that can be dispensed within a given period. These limits are often set by default formulary rules that assume a standard dosing schedule — but many patients on home administration require more frequent dosing, larger supply quantities, or additional ancillary supplies (e.g., infusion tubing, needles, alcohol wipes) than the plan's default allows.

### Why This Denial Is Appealable

Quantity limits are subject to medical-necessity override. If the prescriber has determined, based on clinical assessment and the FDA-approved prescribing information, that the patient requires a quantity above Humana's default limit, the plan must consider that determination. A quantity limit that results in gaps in therapy or under-treatment is clinically harmful and legally challengeable. The appeal should demonstrate that the prescribed quantity is consistent with the FDA-approved label for this patient's weight, diagnosis, and dosing interval.

### Federal Appeal Rights

• Internal appeal: File within the timeframe on the denial notice. Humana must respond within 30 days for standard pre-service appeals.
• External review (ACA §2719 / ERISA §503): After a final internal denial, independent external review is available, generally within four months of the final denial.
• Expedited review: Available if standard timelines would seriously jeopardize health; decisions typically required within 72 hours.

### Documentation to Gather

1. Prescriber quantity-justification letter: A letter from the treating physician explaining why the prescribed quantity — calculated per the FDA-approved label — is necessary for this patient and why the plan's default limit is insufficient. 2. Dosing-calculation basis: Chart documentation of the clinical factors (e.g., body weight, disease severity, dosing frequency) that drive the required quantity, without specifying the numeric amounts in the appeal letter itself — those belong in the prescriber's clinical documentation. 3. FDA prescribing label: The relevant section of the label describing how dose and quantity are calculated, confirming the prescribed amount is within the approved dosing range. 4. Supply-use records: If the patient has been on therapy and has documentation of actual supply consumption, include this to demonstrate that the requested quantity reflects real-world use. 5. Clinical-consequence statement: A prescriber statement describing the clinical consequences of under-dosing or supply gaps for this patient.

### Criteria-Mapping Structure

Obtain Humana's quantity-limit policy for the specific drug and home-administration supply. Identify each criterion used to set or override the limit. For each criterion, provide the chart documentation or prescriber attestation that satisfies it. If the policy allows a quantity-limit exception for medical necessity, invoke that exception explicitly and provide the supporting evidence.

Confirm current quantity-limit criteria with Humana's published coverage policy and the FDA-approved prescribing label.